Genetic Makeup May Explain Why Some Women Smokers Develop Breast Cancer While Others Don't, UB Study in JAMA Reports

November 11, 1996

BUFFALO, N.Y. -- The answer to the question of whether smoking increases a women's risk of developing breast cancer may lie in her genes, researchers at the University at Buffalo and the National Cancer Institute have found.

Results of their study, the first to consider genetic variability as a factor in a person's breast-cancer susceptibility to the carcinogens in cigarette smoke, will be published in the Nov. 13 issue of the Journal of the American Medical Association.

The results showed that postmenopausal women born with the slow-acting gene for N-acetyltransferase (NAT2), an enzyme known to detoxify carcinogenic compounds in cigarette smoke, and who smoked more than a pack of cigarettes a day 20 years before diagnosis, had seven times the risk of developing breast cancer than women born with the fast-acting gene.

The risk was highest for women who began smoking before the age of 18.

The two genotypes are referred to as slow or fast acetylators. No relationship was found between genotypes and risk of breast cancer among premenopausal women who smoked.

Christine Ambrosone, Ph.D., who conducted the research while a post-doctoral fellow in the UB Department of Social and Preventive Medicine, said the findings provide new insight into why previous epidemiologic studies may have failed to show a consistent association between cigarette smoking and breast cancer, when the association is clear in many other organs.

"These findings on breast cancer require substantial replication, but the potential implications may be important," said Ambrosone, now a research epidemiologist at the National Center for Toxicological Research in Arkansas.

"If further investigations in other study populations reveal similar associations between NAT2 genotype, cigarette smoking and breast-cancer risk, it would be an important insight into the etiology of this disease," she added. "It is one more cancer site in which cigarette smoking has been implicated."

Earlier studies showed that smokers with the slow-acetylation genotype for NAT2 had higher levels of tobacco's carcinogenic compounds in their bloodstream, and were at higher risk of developing bladder cancer, a disease known to be associated with cigarette smoking. Components of cigarette smoke also have been shown to cause breast cancer in rodents.

To investigate the possibility that slow-versus-fast acetylation could affect the incidence of breast cancer among smokers, the researchers used data from an earlier case-control study of the disease. Extensive data were gathered on medical and reproductive history and blood samples were collected for DNA analysis. Researchers were able to obtain genetic data from the blood samples of 398 postmenopausal women (185 cases and 213 controls), and 233 premenopausal women (119 cases and 213 controls). All participants were Caucasian.

A food-consumption record for the two years prior to the interview and a lifetime smoking history also were obtained.

Analysis showed a strong association between smoking and breast cancer in postmenopausal women with the slow-acetylation genotype. The risk was highest for women who began smoking before the age of 18. Intensity of smoking -- the number of cigarettes smoked per day at two, 10 and 20 years prior to the interview -- appeared to be more significant than duration of smoking. Among slow acetylators, there was a four-fold increase in risk for women who smoked more than a pack a day in both the distant and recent past.

Among rapid acetylators, there were no significant associations between breast-cancer risk and total years smoked, packs per average year or pack-years smoked. Neither genotype nor smoking history was associated independently with cancer risk.

Ambrosone said that the differences in cancer risk for pre- and postmenopausal women could be caused by a number of factors, among them: Additional researchers contributing to the study were Jo L. Freudenheim, Ph.D.; Saxon Graham, Ph.D.; John E. Vena, Ph.D.; John R. Brasure; Arthur M. Michalek, Ph.D.; Rosemary Laughlin, Ph.D.; James R. Marshall, Ph.D., and Takuma Nemoto, M.D., all from the UB Department of Social and Preventive Medicine.

Also, K. Gillenwater, Anita Harrington and Peter G. Shields, M.D., from the

Laboratory of Human Carcinogenesis, National Cancer Institute.

Portions of this study were presented at the American Association for Cancer Research meeting in Toronto in March.
-end-


University at Buffalo

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.